Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: A retrospective analysis-Reference-Cited by-同舟云学术

Comparison of comorbidities and adverse events in dermatology and rheumatology patients prescribed tofacitinib: A retrospective analysis

Published:2023-11 Issue: Volume: Page:
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Needle Carli D.,Klein Elizabeth J.,Gjonaj Jessica,Nohria Ambika,Karim Maria,Liu Lynn,Shah Jinal,Betensky Rebecca A.,Garshick Michael,Lo Sicco Kristen,Karagounis Theodora K.

Funder

National Institutes of Health

NIAMS

Pfizer Inc

Publisher

Elsevier BV

Subject

Dermatology

Reference5 articles.

1. JAK inhibitors in dermatology: the promise of a new drug class;Damsky;J Am Acad Dermatol,2017

2. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring;Samuel;Dermatol Ther (Heidelb),2023

3. Off-label studies on tofacitinib in dermatology: a review;Tegtmeyer;J Dermatolog Treat,2021

4. Reply to: “Special editorial: when prescribing Janus Kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”;King;J Am Acad Dermatol,2022

5. JAK in the [Black] box: a dermatology perspective on systemic JAK inhibitor safety;Elmariah;Am J Clin Dermatol,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata;Journal of the American Academy of Dermatology;2024-07

2. Navigating the Atopic Dermatitis Toolbox: Challenging Scenarios and Shared Decision Making;Annals of Allergy, Asthma & Immunology;2023-12